A study reveals that pancreatic ductal adenocarcinoma morphology predicts survival after surgery, impacting patient selection and prognosis.

• 400 patients analyzed, identifying 10 morphologic subtypes; gland-forming was most common (41.8%).
• Heterogeneous tumors (38.3% of cases) are linked to worse outcomes, including higher nodal metastasis and lower survival rates (median 30.1 months).

Consider integrating morphologic subtype and heterogeneity in pathology reports to refine surgical decision-making.

• Subtype survival ranged from 19.1 to 47.0 months, showing significant variability based on tumor type.